Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents - 23/10/21
Doi : 10.1016/j.jpeds.2021.06.083
Jenna Schauer, MD ⁎ 
, Sujatha Buddhe, MD, MS, Jessica Colyer, MD, MBA, Eyal Sagiv, MD, PhD, Yuk Law, MD, Sathish Mallenahalli Chikkabyrappa, MD, Michael A. Portman, MD
, Sujatha Buddhe, MD, MS, Jessica Colyer, MD, MBA, Eyal Sagiv, MD, PhD, Yuk Law, MD, Sathish Mallenahalli Chikkabyrappa, MD, Michael A. Portman, MD Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA
∗Reprint requests: Jenna Schauer, MD, 4800 Sandpoint Way NE, Seattle, WA 98105.4800 Sandpoint Way NESeattleWA98105
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Reports have emerged of myocarditis and pericarditis predominantly after the second dose of the coronavirus disease messenger ribonucleic acid vaccine. We describe 13 patients aged 12-17 years who presented with chest pain within 1 week after their second dose of the Pfizer vaccine and were found to have elevated serum troponin levels and evidence of myopericarditis.
Le texte complet de cet article est disponible en PDF.Keywords : myocarditis, COVID-19 vaccine
Abbreviations : CMR, COVID-19, LV, LVEF, mRNA
Plan
| The authors declare no conflicts of interest. |
© 2021
Elsevier Inc. Tous droits réservés.
Vol 238
P. 317-320 - novembre 2021 Retour au numéro
Article précédent
- Real-World Evidence for Assessing Treatment Effectiveness and Safety in Pediatric Populations
- Daniel B. Horton, Michael D. Blum, Mehmet Burcu
- Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent
- Prashant K. Minocha, Donna Better, Rakesh K. Singh, Tasneem Hoque
Bienvenue sur EM-consulte, la référence des professionnels de santé.